Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists | Medical Education and Training | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Comment from a Physician
    Gary Spitzer |
    How we can believe that talks are not biased, minimizing side effects, not addressing the selection of the patients relative to the real world? The analysis does not even include rewards from CME events, and is potentially still missing other sources.

    With this percentage of the physicians' gross income dependent on drug companies, how can they not be conflicted?

    All medical schools should have a cap of $10,000-20,000 excluding the expenses of travel and accommodation. This way we would hear from a more diverse set of speakers with more hands-on experience, and not just traveling KOL's, who
    have their fellows treat the patient or junior staff.
    Research Letter
    March 23, 2020

    Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists

    Author Affiliations
    • 1Knight Cancer Institute, Division of Hematology Oncology, Oregon Health & Science University, Portland
    • 2Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland
    • 3Now with Center for Indigenous Health Research and Policy, Oklahoma State University, Tulsa
    • 4Department of Analytics, Northwest Permanente, Portland, Oregon
    JAMA Intern Med. 2020;180(5):797-799. doi:10.1001/jamainternmed.2020.0090

    Direct payments from industry to academic physicians are common in the US and differ from payments to medical centers for clinical research.1,2 Although most US medical schools have conflict of interest policies for faculty members,3 the restrictions vary.1 We compared industry payments with annual salary in a cohort of academic oncologists at US public medical schools.

    From a 2016 study,4 we obtained a list of 24 US medical schools that provide public employee salary data and recorded all faculty member names from the oncology departments’ websites. We obtained 2017 annual salaries and job titles for faculty members with medical degrees from state-specific public salary databases. The eFigure in the Supplement shows the development of the analytical cohort of 630 faculty oncologists at 14 medical schools from 9 states; 5 schools were in California. We excluded faculty members not found in a 2017 salary database and those with salaries less than $100 000, because such salaries may represent incomplete reporting of pay or the pay of part-time or retired faculty members. We also excluded the faculty of medical schools with fewer than 10 oncology faculty members listed.